That trade-off may soon change. New clinical trial data suggests a once-daily pill called zasocitinib may provide the clear ...
A TYK2 inhibitor in development shows superior efficacy to placebo and apremilast for treating psoriasis, with no new safety ...
A high proportion of patients with moderate to severe plaque psoriasis achieved long-term on-treatment remission for 3 years ...
High rates of complete skin clearance achieved at Week 24 and Week 52 in ICONIC-ADVANCE 1 and 2 studies.- Completely clear skin achieved at Week 52 in nearly 60% of adolescents treated with ...
Opinion
Everyday Health on MSNOpinion
Step therapy for psoriasis: What is it and how does it affect your treatment?
Understand how step therapy affects psoriasis treatment. Learn about the ‘fail first’ process, the impact of treatment delays, and how to work with your dermatologist to appeal insurance denials.
The U.S. Food and Drug Administration has approved Johnson & Johnson's Icotyde (icotrokinra), an interleukin-23 (IL-23) ...
Biologics as a first-line systemic therapy are associated with better clinical outcomes and lower risks for chronic comorbidities in patients with moderate-to-severe psoriasis.
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...
In September 2022, the US Food and Drug Administration (FDA) approved Sotyktu (deucravacitinib; Bristol-Myers Squibb Company), a tyrosine kinase 2 (TYK2) inhibitor, for the treatment of moderate to ...
Deucravacitinib showed strong psoriasis control and rapid scalp clearance with mild adverse events in real-world practice.
Adults with moderate to severe plaque psoriasis saw the greatest mean quality-of-life gains with biologic therapy whereas ...
FDA approval covers adults and adolescents ≥12 years (≥88 lbs) with moderate-to-severe plaque psoriasis requiring systemic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results